Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sequential CAR-T Cell Infusion Targeting CD33 and CD123 for Refractory/Relapsed Acute Myeloid Leukaemia

NCT06420063 is registered in ClinicalTrials.gov with Essen Biotech as lead sponsor.

NCT NCT06420063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06420063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sequential CAR-T Cell Infusion Targeting CD33 and CD123 for Refractory/Relapsed Acute Myeloid Leukaemia
Lead sponsor
Essen Biotech
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 10, 2024
Completion date
December 28, 2026
Enrollment
85 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, aml, aml, adult, aml, adult recurrent